Mode
Text Size
Log in / Sign up
Phase 3 N=1,020 Randomized Quadruple-blind Treatment

Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)

Cataract

Enrolled (actual)
1,020
Serious AEs
74.5%
Results posted
Apr 2012
Primary outcome: Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Centrum (Dietary_supplement); Placebo (Other)
Age
Adult, Older Adult · 55+ yrs
Sex
All
Sponsor
National Eye Institute (NEI)
Primary completion
May 2007

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up
227; 255 0.03 sig
SECONDARY
Number of Participants Showing Development or Progression of Nuclear Lens Opacities
84; 118
SECONDARY
Number of Participants Showing Development or Progression of Cortical Lens Opacities
96; 118
SECONDARY
Number of Participants Showing Development or Progression of Posterior Subcapsular Opacities
74; 37
SECONDARY
Number of Participants Undergoing Cataract Surgery
88; 90
SECONDARY
Number of Participants With a Decrease in Visual Acuity
144; 139

Summary

The Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS) is a 13-year study designed primarily to evaluate the safety and efficacy of a vitamin-mineral supplement (Centrum) containing recommended daily-allowance dosage (RDA) in preventing age-related cataract or delaying its progression in participants with early or no cataract at baseline.

Eligibility Criteria

Inclusion Criteria

  • Clinical and photographic diagnosis of early or no age-related cataract
  • Participants with early cataract must have at least one eligible eye with VA score 20/32 or better
  • Participants with no cataract must have VA score 20/32 or better in both eyes.

Exclusion Criteria

  • Advanced cataract
  • Bilateral aphakia or pseudophakia
  • Any ocular disease or condition that might complicate the future evaluation of cataract
  • Regular use of nutritional supplements
  • Failure to take at least 75% of run-in medication
  • Cancer with evidence of recurrence in the past 5 years
  • Major cerebral or cardiovascular events in past 12 months
  • Current participation to other clinical trials
  • Any condition likely to prevent adherence to CTNS follow-up schedule
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00309387). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search